OGN (Organon) Quality Rank


OGN Organon & Co OGN
71 GF Score
Price $13.55
GF Value $14.54
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Organon Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Organon Quality Rank Related Terms

OGN
71GF Score
Organon & Co OGN
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Organon (OGN) Overvalued in 2026?

Based on GuruFocus' analysis, Organon stock appears to be undervalued. The current stock price of $13.55 is trading 6.8% below its estimated GF Value™ of $14.54. GuruFocus considers Organon to be Fairly Valued.

Key valuation signals for OGN:

  • Quality Rank:
  • GF Value™: $14.54 vs. price of $13.55 (6.8% below fair value)
  • GF Score™: 71/100 with 10 warning signs

No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organon Business Description

Address 30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score

Get the complete analysis for OGN

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.55
Price
$14.54
GF Value